Literature DB >> 1535986

TNF impairs in vivo and in vitro natural killer (NK) susceptibility of B16 melanoma cells.

G Palmieri1, S Morrone, P L Lollini, C De Giovanni, G Nicoletti, P Nanni, L Frati, A Santoni.   

Abstract

Tumour necrosis factor alpha (TNF) is a multipotent cytokine which affects many biological properties of both normal and neoplastic cells. Here we show that treatment with TNF reduces B16-A melanoma cell susceptibility to normal and in vivo- and in vitro-activated NK cell-mediated killing. This resistance is associated with an enhancement of B16-A metastatic potential in normal syngeneic mice, but not in anti-asialo GM1-treated animals, further supporting the NK dependence of TNF-induced enhancement of metastatic ability. A significant increase of MHC class I expression on B16-A murine melanoma cells is observed after TNF treatment. In all these effects TNF interacts positively with interferon gamma (IFN gamma). Taken together, these results indicate that TNF treatment negatively affects the susceptibility of B16-A murine melanoma to NK effectors in vivo and in vitro. This decreased susceptibility may be related, at least in part, to enhanced expression of MHC class I antigens on tumour cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535986     DOI: 10.1111/j.1365-3083.1992.tb02860.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

2.  Augmentation of Cytolytic Activity in Murine Natural Killer Cells and Inhibition of Tumor Growth by the Ethanol Fraction of Oyster Extract.

Authors:  Kaito Sakaguchi; Ming Zhong; Saeko Kawai; Yoshio Shimizu; Eiichi Gohda
Journal:  Integr Cancer Ther       Date:  2016-12-05       Impact factor: 3.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.